Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/133077
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hanquet, Germaine | - |
dc.contributor.author | Krizova, Pavla | - |
dc.contributor.author | Valentiner-Branth, Palle | - |
dc.contributor.author | Ladhani, Shamez N. | - |
dc.contributor.author | Nuorti, J. Pekka | - |
dc.contributor.author | Lepoutre, Agnes | - |
dc.contributor.author | Mereckiene, Jolita | - |
dc.contributor.author | Knol, Mirjam | - |
dc.contributor.author | Winje, Brita A. | - |
dc.contributor.author | Ciruela, Pilar | - |
dc.contributor.author | Ordobas, Maria | - |
dc.contributor.author | Guevara, Marcela | - |
dc.contributor.author | McDonald, Eisin | - |
dc.contributor.author | Morfeldt, Eva | - |
dc.contributor.author | Kozakova, Jana | - |
dc.contributor.author | Slotved, Hans-Christian | - |
dc.contributor.author | Fry, Norman K. | - |
dc.contributor.author | Rinta-Kokko, Hanna | - |
dc.contributor.author | Varon, Emmanuelle | - |
dc.contributor.author | Corcoran, Mary | - |
dc.contributor.author | Van der Ende, Arie | - |
dc.contributor.author | Vestrheim, Didrik F. | - |
dc.contributor.author | Muñoz-Almagro, Carmen | - |
dc.contributor.author | Latasa, Pello | - |
dc.contributor.author | Castilla, Jesús | - |
dc.contributor.author | Smith, Andrew | - |
dc.contributor.author | Henriques-Normark, Birgitta | - |
dc.contributor.author | Whittaker, Robert | - |
dc.contributor.author | Pastore Celentano, Lucia | - |
dc.contributor.author | Savulescu, Camelia | - |
dc.contributor.author | SpIDnet/I-MOVE+ Pneumo Group | - |
dc.date.accessioned | 2019-05-13T11:57:12Z | - |
dc.date.available | 2019-05-13T11:57:12Z | - |
dc.date.issued | 2019-05 | - |
dc.identifier.issn | 0040-6376 | - |
dc.identifier.uri | http://hdl.handle.net/2445/133077 | - |
dc.description.abstract | Background: pneumococcal conjugate vaccines (PCVs) have the potential to prevent pneumococcal disease through direct and indirect protection. This multicentre European study estimated the indirect effects of 5-year childhood PCV10 and/or PCV13 programmes on invasive pneumococcal disease (IPD) in older adults across 13 sites in 10 European countries, to support decision-making on pneumococcal vaccination policies. Methods: for each site we calculated IPD incidence rate ratios (IRR) in people aged ≥65 years by serotype for each PCV10/13 year (2011-2015) compared with 2009 (pre-PCV10/13). We calculated pooled IRR and 95% CI using random-effects meta-analysis and PCV10/13 effect as (1 - IRR)*100. Results: after five PCV10/13 years, the incidence of IPD caused by all types, PCV7 and additional PCV13 serotypes declined 9% (95% CI -4% to 19%), 77% (95% CI 67% to 84%) and 38% (95% CI 19% to 53%), respectively, while the incidence of non-PCV13 serotypes increased 63% (95% CI 39% to 91%). The incidence of serotypes included in PCV13 and not in PCV10 decreased 37% (95% CI 22% to 50%) in six PCV13 sites and increased by 50% (95% CI -8% to 146%) in the four sites using PCV10 (alone or with PCV13). In 2015, PCV13 serotypes represented 20-29% and 32-53% of IPD cases in PCV13 and PCV10 sites, respectively. Conclusion: overall IPD incidence in older adults decreased moderately after five childhood PCV10/13 years in 13 European sites. Large declines in PCV10/13 serotype IPD, due to the indirect effect of childhood vaccination, were countered by increases in non-PCV13 IPD, but these declines varied according to the childhood vaccine used. Decision-making on pneumococcal vaccination for older adults must consider the indirect effects of childhood PCV programmes. Sustained monitoring of IPD epidemiology is imperative. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BMJ Publishing Group | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1136/thoraxjnl-2018-211767 | - |
dc.relation.ispartof | Thorax, 2019, vol. 74, num. 5, p. 211767 | - |
dc.relation.uri | https://doi.org/10.1136/thoraxjnl-2018-211767 | - |
dc.rights | (c) BMJ Publishing Group, 2019 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Malalties bacterianes | - |
dc.subject.classification | Epidemiologia | - |
dc.subject.classification | Vacuna antipneumocòccica | - |
dc.subject.classification | Adults | - |
dc.subject.classification | Infància | - |
dc.subject.classification | Europa | - |
dc.subject.other | Bacterial diseases | - |
dc.subject.other | Epidemiology | - |
dc.subject.other | Pneumococcal vaccine | - |
dc.subject.other | Adulthood | - |
dc.subject.other | Childhood | - |
dc.subject.other | Europe | - |
dc.title | Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 685543 | - |
dc.date.updated | 2019-05-13T11:57:12Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/634446/EU//I-MOVE-plus | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 30355641 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
685543.pdf | 2.47 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.